| Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. | |
| | |
MedLine Citation:
|
PMID: 2221645 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. DESIGN: Two-year, double-blind, randomized clinical trial. SETTING: University medical center. PATIENTS: Fifty postmenopausal women with vertebral fractures recruited by referral. INTERVENTION: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium less than 2.74 mmol/L (less than 11.0 mg/dL) or urine calcium less than 9.96 mmol/d (less than 400 mg/d). MEASUREMENTS AND MAIN RESULTS: After 2 years, the mean dose of calcitriol in the treated group was 0.62 micrograms/d. Bone mineral density of the spine increased 1.94% with calcitriol therapy and decreased 3.92% with placebo (P = 0.001). Total body calcium increased 0.21% with calcitriol therapy and decreased 1.85% with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. CONCLUSION: The treatment of postmenopausal osteoporotic women with synthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy. |
| | |
Authors:
|
J C Gallagher; D Goldgar |
Related Documents
:
|
15539225 - Effect of mg nutriture on the dynamics of administered 25mg exchange in vivo in the rat. 8229785 - Duration and dose-related effects of an orally administered, partially lipophilic polya... 12622925 - Percutaneous estrogen in prevention of early postmenopausal bone loss in chinese women. 10537165 - Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. 9114435 - 9-[3-(2-nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (nlcpq-1... 4096685 - Effect of denervation and/or reserpine-induced changes on adrenomedullary catecholamine... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Annals of internal medicine Volume: 113 ISSN: 0003-4819 ISO Abbreviation: Ann. Intern. Med. Publication Date: 1990 Nov |
Date Detail:
|
Created Date: 1990-11-15 Completed Date: 1990-11-15 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 649-55 Citation Subset: AIM; IM |
Affiliation:
|
Bone Metabolism Unit, Creighton University Medical Center, Omaha, NE 68131. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Biopsy Bone Density / drug effects Bone and Bones / pathology Calcitriol / administration & dosage*, therapeutic use Dose-Response Relationship, Drug Female Fractures, Bone / epidemiology Humans Incidence Middle Aged Osteoporosis, Postmenopausal / drug therapy*, metabolism, pathology |
| Chemical | |
Reg. No./Substance:
|
32222-06-3/Calcitriol |
| Comments/Corrections | |
Comment In:
|
Ann Intern Med. 1991 Mar 15;114(6):519-20
[PMID:
1994801
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary pancreatic hydatid cyst and primordial familial dwarfism
Next Document: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and system...